A new study shows that the VISTA molecule stops the immune system responding to self-antigens, including those presented by cancer cells, so an anti-VISTA antibody could be a possible therapy.
List view / Grid view
Filter the results
In a world first, researchers have grown immune cells from pluripotent stem cells in a dish, which could be used to develop immunotherapies or to test autoimmune disease treatments.
A study has demonstrated the success of new compounds that prevent FOXM1, a transcription factor, from increasing cancer proliferation.
A study has shown that the SVC112 molecule can prevent cancer stem cells from producing more tumour cells in cell lines and mice, with no impact on healthy cells.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
A new study has revealed that the Siah2 protein is crucial to control Tregs in mice, which can reduce the effectiveness of immunotherapies.
Scientists have found that when two specific genes are deleted in benign tumour tissue in the intestines, it more rapidly develops into a tumour that is more likely to become cancerous.
A study has shown that T cells are driven to attack tumours by IL-2 and Blimp-1 in mice, which researchers say could form the basis of cancer therapies.
A study has revealed that activation of syndecan-4 sensory protrusions extending from cells may be a future target for cancer therapy.
A study has shown that using three antibodies with two different mechanisms of action could be a novel way to improve immuno-oncology treatments.
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.